CELH stock forecast models suggest a target range of $98–$108 over the next quarter, thanks to record case sales and aggressive international rollout. RSI currently sits near 60, indicating room for further upside without being overbought. LifeStance Health Group is experiencing steady revenue growth, with forecasts indicating a 13.9% annual increase, surpassing the broader US market's growth rate. Despite recent net losses, the company is expected to achieve profitability within three years. Insider activity shows more substantial buying than selling recently, suggesting confidence in future prospects. The appointment of Sarah Personette to the board enhances leadership with her extensive experience in customer engagement and media sectors, potentially supporting strategic initiatives for growth. Why State Street's Options Volume Just Sent a Bullish Signal CELH stock forecast looks bullish as recent Q1 earnings showed a 36% YoY revenue jump, driven by strong demand in the functional beverage segment. Traders are watching the $92 support level, with potential upside toward $105 if momentum holds.
